Microcephaly, Short Stature, and Impaired Glucose Metabolism 1

1. Disease Information

Overview. Microcephaly, short stature, and impaired glucose metabolism 1 (MSSGM1) is a rare, autosomal recessive multisystem Mendelian syndrome characterized by primary (congenital or early-postnatal) microcephaly with intellectual disability, proportionate short stature, and disturbed glucose homeostasis — typically hyperinsulinemic hypoglycemia in infancy/early childhood evolving into young-onset diabetes mellitus in adolescence or young adulthood (OMIM #616033; MedGen C4014997). It is caused by biallelic (homozygous or compound heterozygous) loss-of-function mutations in TRMT10A (tRNA methyltransferase 10 homolog A), located at chromosome 4q23 (OMIM *616013).

Key identifiers: - OMIM phenotype: #616033 (MSSGM1); gene locus OMIM 616013 (TRMT10A) - MONDO: MONDO:0000208 (per NCBI MedGen cross-reference) - MedGen: C4014997 / UID 863434 - Orphanet: ORPHA:391408 — "Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome" - HGNC: HGNC:28403 (TRMT10A) - Gene location: 4q23; Ensembl: ENSG00000145331 - Note: A phenotypically overlapping but molecularly and nosologically distinct entity exists — MSSGM2 (OMIM #616817), caused by biallelic mutations in IGF2BP1* — and NSMCE2-related primordial dwarfism (OMIM #617253) also has overlapping features (short stature, microcephaly, insulin resistance) but is a separate gene/disorder. These should not be conflated with MSSGM1/TRMT10A.

Synonyms: MSSGM1; TRMT10A deficiency; TRMT10A-related syndrome; "microcephaly, intellectual disability, short stature, and diabetes"; young-onset diabetes with microcephaly.

Data provenance: Knowledge is derived almost entirely from aggregated case reports and small case series (individual patients and consanguineous families) rather than large population-level cohorts or EHR-based studies — consistent with an ultra-rare Mendelian disease with an estimated total of only ~15–20 published cases across the literature to date (multiple independent kindreds: Moroccan, Uzbek Jewish, Israeli/Bedouin, Scottish, Chinese, Turkish).

Sources: - OMIM #616033 - OMIM *616013 TRMT10A - MedGen C4014997 - Orphanet TRMT10A

2. Etiology

Disease-causal factor: MSSGM1 is a monogenic, autosomal recessive disorder caused exclusively by biallelic loss-of-function variants in TRMT10A. There is no known environmental, infectious, or polygenic contribution to the core syndrome — it is a purely genetic/mechanistic disease. TRMT10A encodes a nucleolar tRNA methyltransferase (the human ortholog of yeast Trm10) that catalyzes N1-methylation of guanosine 9 (m¹G9) in the D-loop of multiple cytoplasmic tRNAs.

Genetic risk factors (causal variants reported across kindreds): - c.379G>A (p.Arg127Ter/R127X) — homozygous nonsense mutation, first-described Moroccan consanguineous family (3 siblings) (Igoillo-Esteve et al. 2013, PMID: 24204302) - c.616G>A (p.Gly206Arg/G206R) — homozygous missense mutation at a highly conserved catalytic residue, consanguineous Uzbek Jewish family (3 siblings); in vitro methyltransferase activity assays showed the mutant enzyme had >10⁴-fold reduced methylation activity compared to wild type (Gillis et al. 2014, J Med Genet 51:581–586, DOI: 10.1136/jmedgenet-2014-102282) - p.Glu27Ter (c.79G>T) — homozygous nonsense mutation, Scottish siblings with milder, adult-onset phenotype (Yew et al. 2016, PMID: 26526202) - c.496-1G>A — homozygous canonical splice-acceptor mutation, first reported Chinese/Asian patient (Lin et al. 2020, BMJ Open Diabetes Res Care 8:e001601) - Homozygous contiguous gene deletion encompassing TRMT10A, causing a more severe multisystem phenotype including failure to thrive and delayed puberty (Zung et al. 2015, Am J Med Genet A, DOI: 10.1002/ajmg.a.37341) - Additional homozygous/compound heterozygous TRMT10A variants reported in subsequent case reports (e.g., a case with hypoplastic kidneys, PMID: 33448213; a 2024 case report of microcephaly/diabetes/epilepsy, PMID: 38302348)

All disease-causing variants are inherited in an autosomal recessive pattern, and virtually all reported cases arose in the setting of parental consanguinity, consistent with a rare recessive founder/private-mutation disease.

Environmental/lifestyle risk factors: None established — this is not modified by known environmental exposures; disease expression is driven by genotype (complete vs. partial loss of TRMT10A methyltransferase activity), which correlates with phenotypic severity (see below).

Protective factors: None specifically documented. No modifier genes or protective alleles have been reported. Heterozygous carriers (parents of affected probands) are clinically unaffected, consistent with fully recessive inheritance without a dominant-negative or haploinsufficiency mechanism.

Genotype-phenotype/severity correlation (an important "gene-environment"-adjacent theme): Emerging literature (including a 2026 study on "TRMT10A-Related Neurodevelopmental Disorder Without Metabolic Findings," Ülker Üstebay et al., Human Mutation 2026) suggests residual enzymatic activity of the mutant allele modulates phenotype severity — some hypomorphic alleles produce a neurodevelopmental phenotype (intellectual disability, microcephaly) without the metabolic (diabetes/hypoglycemia) component, broadening the recognized phenotypic spectrum beyond the "full" MSSGM1 triad.

Sources: - Igoillo-Esteve et al. 2013, PLOS Genetics (PMC3814312) - Gillis et al. 2014, J Med Genet (DOI 10.1136/jmedgenet-2014-102282) - Yew et al. 2016, Diabetic Medicine (PMC4995728) - Lin et al. 2020, BMJ Open Diabetes Res Care (PMC7569974) - Zung et al. 2015, Am J Med Genet A - TRMT10A Mutation in a Child with Diabetes... Hypoplastic Kidneys, PMID 33448213 - A rare syndrome: Microcephaly, diabetes mellitus, and epilepsy, PMID 38302348 - TRMT10A-Related Neurodevelopmental Disorder Without Metabolic Findings, Human Mutation 2026

3. Phenotypes

The MSSGM1 phenotype (compiled from MedGen's HPO-term listing and the primary case-series literature) spans neurodevelopmental, growth/skeletal, endocrine-metabolic, and immune domains.

Neurological/developmental

Growth/skeletal

Endocrine/metabolic (the defining "impaired glucose metabolism" component)

Age of onset / progression: Congenital microcephaly and short stature are apparent from birth/infancy. Glucose dysregulation frequently begins as hyperinsulinemic hypoglycemia in infancy or early childhood, transitioning over years to overt diabetes mellitus in the second or third decade — proposed to reflect progressive β-cell loss via apoptosis (see Mechanism section). Severity and the specific metabolic phenotype (hypoglycemia-predominant vs. insulin-resistant diabetes-predominant, vs. purely neurodevelopmental with no metabolic disease) vary by allele and possibly by residual enzymatic activity, per the 2026 phenotype-expansion report. Epilepsy/seizures appear to be a variably penetrant feature rather than universal.

Frequency across the literature: Because MSSGM1 is known from fewer than ~20 published probands, "frequency" data (e.g., % of patients with a given feature) should be treated as descriptive of the small reported case series rather than population-level statistics; frequency qualifiers in a knowledge base entry should be sourced to specific cohort counts (e.g., "3/3 siblings" in a given family report) rather than generalized percentages.

Quality of life impact: Not formally studied with standardized instruments (no EQ-5D/SF-36 data identified); qualitatively, affected individuals face lifelong intellectual disability, need for insulin/metabolic management, and growth-related morbidity, but no dedicated QOL study was found in the literature reviewed.

Sources: - MedGen C4014997 — clinical feature listing - Igoillo-Esteve et al. 2013 (PMC3814312) - Gillis et al. 2014, J Med Genet - Yew et al. 2016 (PMC4995728) - Lin et al. 2020 (PMC7569974)

4. Genetic/Molecular Information

Causal gene: TRMT10A (HGNC:28403), chromosome 4q23, Ensembl ENSG00000145331. Gene-level OMIM entry: *616013.

Protein: tRNA methyltransferase 10 homolog A — a nucleolar enzyme, mammalian ortholog of S. cerevisiae Trm10, that catalyzes formation of N1-methylguanosine at position 9 (m¹G9) in the D-loop of multiple cytoplasmic tRNAs. TRMT10A localizes to the nucleolus in both β-cells and non-β-cells, the site of tRNA processing/modification (Igoillo-Esteve et al. 2013). TRMT10A is ubiquitously expressed but enriched in brain and pancreatic islets, directly consistent with the two principal affected tissues in MSSGM1 (Igoillo-Esteve et al. 2013; OMIM *616013).

Reported pathogenic variants (all biallelic, loss-of-function or severely hypomorphic): - p.Arg127Ter (c.379G>A) — complete loss via nonsense-mediated decay (NMD); no detectable mRNA/protein (Igoillo-Esteve 2013) - p.Gly206Arg (c.616G>A) — missense at a conserved catalytic residue; methylation activity reduced >10⁴-fold in vitro (Gillis 2014) - p.Glu27Ter (c.79G>T) — nonsense, presumed NMD (Yew 2016) — associated with a milder phenotype (adult-onset diabetes, normalized head circumference, minimal dysmorphism), suggesting some genotype-severity correlation - c.496-1G>A — canonical splice acceptor variant (Lin et al. 2020) - Contiguous gene deletion encompassing TRMT10A (Zung et al. 2015) — more severe multisystem phenotype

Variant classification: Per ACMG/AMP framework, the nonsense and canonical splice-site variants are consistently classified pathogenic (complete loss of function); the G206R missense is functionally validated as pathogenic via direct enzymatic assay. Genes/variants are catalogued in ClinVar and GenCC (TRMT10A: GenCC HGNC:28403).

Functional consequence: Loss-of-function — all characterized variants abolish or nearly abolish tRNA m¹G9 methyltransferase activity, leading to hypomodified tRNAs.

Allele frequency: TRMT10A biallelic pathogenic variants are each private/family-specific (found in single consanguineous kindreds); no common population founder allele has been reported. Carrier frequency has not been systematically estimated in large population databases (e.g., gnomAD) for any specific pathogenic allele given the rarity and family-specific nature of variants identified to date.

Origin: Germline (constitutional), consistent with a classic autosomal recessive Mendelian disease — not a somatic/cancer-associated gene.

Modifier genes/epigenetics: None specifically identified for MSSGM1. No DNA methylation, histone modification, or chromatin-level disease mechanism has been reported for TRMT10A-related disease; the pathology is a direct enzymatic (RNA-modification) loss-of-function, not an epigenetic-regulatory mechanism.

Chromosomal abnormalities: One reported case involved a homozygous contiguous gene deletion spanning the TRMT10A locus (Zung et al. 2015), rather than a point mutation — illustrating that both intragenic pathogenic variants and larger structural deletions of the locus can cause the syndrome.

Suggested ontology terms: HGNC:28403 (TRMT10A); GO:0002939 (tRNA N1-guanine methylation) / GO:0160104 (tRNA (guanine-N1)-methyltransferase activity, if applicable term exists) for molecular function; GO:0005730 (nucleolus) for subcellular localization.

Sources: - OMIM *616013 TRMT10A - Igoillo-Esteve et al. 2013 (PMC3814312) - Gillis et al. 2014 - GenCC TRMT10A - GeneCards TRMT10A

5. Environmental Information

No environmental toxin, radiation, pollutant, occupational exposure, infectious agent, or lifestyle factor has been implicated as a cause or trigger of MSSGM1 in the literature reviewed. This is a purely monogenic disease. No infectious-agent association applies. Not applicable for this disorder beyond standard supportive-care/diet management of secondary diabetes (see Treatment).

6. Mechanism / Pathophysiology

Core molecular defect → cellular consequence → organ phenotype causal chain:

1. Molecular lesion: Biallelic TRMT10A loss-of-function → loss of nucleolar tRNA m¹G9 methyltransferase activity → accumulation of hypomodified cytoplasmic tRNAs.
2. Cellular consequence (pancreatic β-cells): Igoillo-Esteve et al. (2013) demonstrated directly that "TRMT10A silencing induces rat and human β-cell apoptosis" — i.e., loss of TRMT10A function triggers programmed cell death specifically in insulin-producing β-cells, likely via unresolved translational/proteostatic stress from hypomodified tRNAs impairing translational fidelity/efficiency.
3. Cellular consequence (neurons): The same mechanistic principle is proposed to operate in the developing brain — "TRMT10A deficiency negatively affects β-cell mass and the pool of neurons in the developing brain" (Igoillo-Esteve et al. 2013) — i.e., reduced neuronal progenitor pool/survival during neurodevelopment, producing primary microcephaly and the associated intellectual disability.
4. Organ/systemic consequence — glucose homeostasis: Progressive β-cell apoptosis initially manifests as hyperinsulinemic hypoglycemia (proposed to reflect dysregulated/excessive insulin release from stressed or dying β-cells in early life) and evolves over time, as β-cell mass is progressively lost, into insulin-deficient/insulin-resistant diabetes mellitus in adolescence/young adulthood (Gillis et al. 2014: "TRMT10A deficiency accounts for abnormalities in glucose homeostasis initially manifesting both ketotic and non-ketotic hypoglycaemic events with transition to diabetes in adolescence, perhaps as a consequence of accelerated β cell apoptosis"). A separate arm — peripheral insulin resistance — is also directly documented (low Matsuda index in Yew 2016; marked insulin resistance responsive to metformin in Lin et al. 2020), suggesting the metabolic phenotype has both a β-cell-apoptotic/insulin-secretory component and a peripheral insulin-sensitivity component.
5. Organ/systemic consequence — CNS: Impaired neuronal pool generation during development → primary microcephaly, global developmental delay, intellectual disability, and (in a subset) epilepsy.
6. Growth: Short stature is proportionate and likely reflects a combination of the systemic translational-stress mechanism (affecting growth-plate chondrocytes and other proliferating tissues generally) plus downstream endocrine dysfunction (delayed puberty), though a specific growth-hormone-axis lesion has not been demonstrated.

Upstream vs. downstream: The TRMT10A enzymatic defect is the single upstream initiating lesion; β-cell apoptosis/dysfunction and impaired neurodevelopmental neuron pool are parallel (not sequential) downstream consequences occurring in different tissues due to the same ubiquitous but tissue-enriched enzyme loss — i.e., a "single-gene, two-tissue convergent phenotype" pattern (analogous in structure to modules like metabolic_intoxication_decompensation but distinct in that here the same molecular lesion independently damages two enriched-expression tissues rather than one metabolic block causing a toxic cascade).

Cell types/tissues involved: - Pancreatic islet β-cells (insulin-secreting) - Neural progenitor cells / developing cortical neurons

Suggested ontology terms: - GO:0006915 apoptotic process (β-cell apoptosis) - GO:0002943 tRNA dihydrouridine synthesis / GO:0030488 tRNA methylation (general parent term; more specific m¹G9 term may need verification via OAK) - CL:0000169 type B pancreatic cell (β-cell) - CL:0011020 neural progenitor cell / CL:0000540 neuron - UBERON:0000006 islet of Langerhans - UBERON:0000955 brain / UBERON:0001851 cortex

Molecular profiling: No transcriptomic, proteomic, or single-cell datasets specific to human TRMT10A-deficient tissue were identified in this search; the primary functional evidence is (a) direct in vitro enzymatic methyltransferase assays on recombinant mutant protein (Gillis 2014) and (b) siRNA-knockdown apoptosis assays in rat/human β-cell lines (Igoillo-Esteve 2013). No CRISPR screen or multi-omics human-tissue dataset for this specific gene/disease was found.

Sources: - Igoillo-Esteve et al. 2013, PLOS Genetics (PMC3814312) — direct quotes above - Gillis et al. 2014, J Med Genet — direct quote above - Yew et al. 2016 (PMC4995728) — Matsuda index data

7. Anatomical Structures Affected

Organ level: - Primary: Brain (microcephaly, structural under-development), pancreas (endocrine islets — β-cell loss) - Secondary/complication-related: Kidney (hypoplastic kidneys reported in one case), skeletal system (short stature, scoliosis, osteoporosis), reproductive/endocrine axis (delayed puberty, primary amenorrhea) - Body systems: Nervous system, endocrine system, skeletal system, and (in one case) renal system

Tissue/cell level: - Pancreatic islet β-cells (CL:0000169) - Neural progenitor cells / cortical neurons during development - Bone (osteoporosis) — osteoblast/osteoclast balance not specifically studied

Subcellular level: - Nucleolus (GO:0005730) — the specific subcellular site where TRMT10A functions and where tRNA modification occurs, per Igoillo-Esteve et al. 2013 ("TRMT10A localizes to the nucleolus of β- and non-β-cells") - Cytoplasm — the ultimate site of action of the modified tRNAs during translation

Localization/laterality: No lateralization is described; microcephaly and short stature are symmetric/systemic findings; hypoplastic kidney was reported without specified laterality detail in the abstract reviewed.

Suggested UBERON terms: UBERON:0000955 (brain), UBERON:0001264 (pancreas), UBERON:0000006 (islet of Langerhans), UBERON:0002113 (kidney), UBERON:0001474 (bone element).

8. Temporal Development

• Onset: Congenital/perinatal for microcephaly and short stature (present from birth); infancy/early childhood for hyperinsulinemic hypoglycemia; adolescence to young adulthood for overt diabetes mellitus (reported range: age 14–22 in the original Moroccan family vs. mid-20s in the milder Scottish family, per Yew 2016) — i.e., a chronic, congenital-onset, progressive disorder with a delayed/evolving metabolic phenotype.
• Progression: The metabolic axis specifically shows a biphasic progression — early hypoglycemia (proposed β-cell dysregulation/early apoptosis phase) transitioning to diabetes (progressive β-cell loss) over years. Neurodevelopmental features (intellectual disability, microcephaly) are generally static/non-progressive once established, though in some patients head circumference "normalized" with growth (Yew 2016), suggesting variable postnatal catch-up in milder alleles.
• Disease course pattern: Chronic, lifelong; not relapsing-remitting. No spontaneous remission of the metabolic or neurodevelopmental features has been described.
• Critical periods: Neurodevelopment (prenatal through early childhood) appears to be the critical window during which loss of TRMT10A most directly determines the eventual degree of microcephaly/intellectual disability, given the mechanism operating on the developing neuronal progenitor pool.

Sources: as above (Igoillo-Esteve 2013; Gillis 2014; Yew 2016).

9. Inheritance and Population

• Epidemiology: MSSGM1 is an ultra-rare disease. No formal prevalence or incidence estimate (per 100,000) has been published; the disease is known from approximately 15–20 reported probands worldwide across independent kindreds (Moroccan, Uzbek Jewish/Israeli, Scottish, Chinese, Turkish, and others), consistent with Orphanet-level "ultra-rare" classification. A knowledge-base entry should record prevalence_class: NOT_YET_DOCUMENTED or a qualitative ULTRA_RARE band rather than a specific numeric rate, given the absence of a published epidemiological study.
• Inheritance pattern: Autosomal recessive (AR) — confirmed across every reported kindred (biallelic variants, unaffected heterozygous parents, consanguinity in essentially all reported families).
• Penetrance: Appears complete for the core phenotype (microcephaly, short stature) among biallelic carriers reported to date, though the specific metabolic sub-phenotype (hypoglycemia vs. diabetes vs. isolated neurodevelopmental disease without metabolic findings, per the 2026 report) is variable/genotype-dependent.
• Expressivity: Variable — e.g., the p.Glu27Ter Scottish family had a substantially milder, later-onset phenotype (adult-onset diabetes, normalized head circumference, minimal dysmorphism) compared with the original Moroccan R127X family and the Uzbek Jewish G206R family (severe congenital microcephaly, childhood-onset hyperinsulinemic hypoglycemia, seizures).
• Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not specifically reported.
• Founder effects: Each reported pathogenic variant appears to be family/population-specific (Moroccan founder R127X; Uzbek Jewish founder G206R), consistent with multiple independent founder mutations in geographically/ethnically distinct consanguineous populations rather than one recurring global founder allele.
• Consanguinity: A major contributing factor — nearly every published kindred involved first-cousin or otherwise consanguineous unions, as expected for a fully recessive ultra-rare disease.
• Carrier frequency: Not established in population reference databases for any specific allele (each variant is private/rare).
• Population demographics: Reported cases span Moroccan, Israeli/Uzbek Jewish, Scottish/European, and Chinese/East Asian populations, indicating the disease is not restricted to a single ethnic group, though each specific pathogenic allele so far has been population/family-specific.
• Sex ratio: No skewed sex ratio has been reported; both males and females affected across kindreds (though some phenotypes like delayed thelarche/primary amenorrhea are necessarily reported in affected females).
• Age distribution: Presentation from birth (microcephaly, short stature) through childhood (hypoglycemia) to adolescence/young adulthood (diabetes diagnosis); no adult-onset-only presentation has been described absent the childhood neurodevelopmental features.

10. Diagnostics

Laboratory tests: - Fasting glucose, insulin, C-peptide (to characterize hyperinsulinemic hypoglycemia in early presentation) - HbA1c (for diabetes monitoring — e.g., decreased from 14.4% to 6.8% with metformin in the Lin et al. 2020 case) - Oral glucose tolerance testing with Matsuda index calculation for insulin sensitivity (used in Yew 2016) - Anti-GAD65 antibody (reported feature; may be used to help exclude autoimmune/type 1 diabetes in differential diagnosis) - Insulinogenic index / disposition index for β-cell function assessment

Genetic testing: - Targeted gene testing / gene panel for TRMT10A is the primary recommended approach once the clinical triad (microcephaly + short stature + glucose dysregulation) is recognized; several diagnoses were made via targeted next-generation sequencing panels for monogenic diabetes (Yew 2016; Lin 2020). - Whole-exome sequencing (WES) was the discovery method in the original families (Igoillo-Esteev 2013; Gillis 2014) and remains appropriate when the phenotype is not immediately recognized as monogenic-diabetes-related. - Chromosomal microarray (CMA) is relevant given at least one reported case involved a contiguous gene deletion encompassing TRMT10A (Zung et al. 2015) rather than a point mutation — CMA/deletion analysis should be considered when sequencing is negative but phenotype is compatible. - Standard monogenic-diabetes gene panels (e.g., MODY panels) may include TRMT10A in comprehensive versions; clinicians are advised (per Yew et al. 2016) that "TRMT10A sequencing should be considered in children or adults with young-onset diabetes who have a history of intellectual disability, microcephaly and epilepsy."

Imaging: Head circumference/growth charting for microcephaly; brain MRI to characterize any structural abnormality (specific MRI findings were not detailed in the sources reviewed here, and would need per-case verification before citing generically).

Clinical criteria: No formal consensus diagnostic criteria/society guideline was identified (consistent with the disease's rarity); diagnosis rests on the clinical triad (microcephaly + short stature + glucose dysregulation) plus confirmatory molecular genetic testing.

Differential diagnosis: Should include other monogenic diabetes/growth-microcephaly syndromes — notably MSSGM2 (IGF2BP1), NSMCE2-related primordial dwarfism, Wolcott-Rallison syndrome, and other syndromic causes of congenital hyperinsulinism/primordial dwarfism with microcephaly (e.g., MOPD II/PCNT). Molecular confirmation is essential to distinguish these overlapping phenotypes.

Screening: No population newborn-screening or carrier-screening program specifically targets TRMT10A (disease too rare); targeted carrier testing may be offered within consanguineous families with a known proband variant.

11. Outcome/Prognosis

• Survival/mortality: No specific survival statistics or life-expectancy data were identified in the sources reviewed; the disease has not been characterized as immediately life-threatening in reported cases, though severe/prolonged hypoglycemic episodes in infancy carry inherent neurological risk if unrecognized/untreated, and uncontrolled diabetes carries the usual long-term complication risk.
• Morbidity: Lifelong intellectual disability and short stature are essentially fixed; ongoing management burden from diabetes/insulin resistance, and skeletal complications (scoliosis, osteoporosis) may accrue over time.
• Complications: Diabetes-related complications (standard long-term diabetic complications would be expected if poorly controlled, though not specifically documented in this small case literature); seizure disorder in a subset; renal hypoplasia in at least one reported case.
• Recovery potential: The neurodevelopmental component (microcephaly, intellectual disability) is not reversible; the metabolic component is manageable with standard diabetes therapy, and in at least one case responded very well to metformin (HbA1c improved from 14.4% to 6.8% within 3 months; Lin et al. 2020), indicating meaningful treatment-responsive disease course for the insulin-resistant subtype.
• Prognostic factors: Genotype severity appears to correlate with phenotype severity (complete loss-of-function alleles like R127X and G206R associated with more severe congenital phenotype vs. the milder p.Glu27Ter Scottish kindred) — this is the closest available "prognostic biomarker," i.e., genotype itself, though small numbers preclude a rigorous prognostic model.

12. Treatment

There is no disease-modifying or curative therapy for the underlying TRMT10A enzymatic defect; management is entirely symptomatic/supportive, targeted at the metabolic and neurodevelopmental manifestations.

Pharmacotherapy (metabolic management): - Insulin therapy — for hypoglycemia management in infancy (in the hyperinsulinemic-hypoglycemia phase) and/or for insulin-deficient diabetes later in disease course. NCIT term: NCIT:C15986 (Pharmacotherapy) generically, or a more specific insulin/glucose-management term if available. - Metformin — demonstrated highly effective for the insulin-resistance-predominant metabolic phenotype (HbA1c 14.4%→6.8% in 3 months in the Chinese case; Lin et al. 2020). therapeutic_agent: CHEBI:6801 (metformin); treatment_term: NCIT:C15986 Pharmacotherapy. - Standard diabetes monitoring and dietary management for glucose control (dietary intervention, NCIT:C15447).

Supportive/rehabilitative: - Physical therapy, occupational therapy, and special-education/developmental support for intellectual disability and motor delay (NCIT:C15302 Physical Therapy; general developmental/rehabilitation services NCIT:C15315). - Management of seizures with standard antiepileptic therapy where epilepsy is present (specific agent not detailed per-case in sources reviewed). - Endocrine management of delayed puberty (e.g., hormone replacement as clinically indicated). - Orthopedic monitoring/management for scoliosis and osteoporosis.

Genetic counseling: Recommended for affected families given the autosomal recessive inheritance and typically consanguineous presentation (NCIT:C15240 Genetic Counseling).

Experimental/advanced therapeutics: No gene therapy, RNA-based therapy, or targeted molecular therapy specific to TRMT10A deficiency has been reported or is in clinical trials, based on the sources reviewed. No NCT-registered trial specific to this disease was identified.

Treatment strategy: Because the metabolic phenotype has (at least) two distinct pathophysiological arms — β-cell apoptosis/insulin deficiency vs. peripheral insulin resistance — treatment should be individualized based on which pattern predominates (insulin therapy vs. insulin-sensitizing agents like metformin), as illustrated directly by the divergent management needs and metformin responsiveness reported across cases.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (monogenic recessive disease); the only "primary prevention" avenue is genetic counseling and reproductive risk communication in consanguineous families with a known TRMT10A pathogenic variant, including discussion of carrier testing, prenatal diagnosis, or preimplantation genetic diagnosis (PGD) where desired and available (NCIT:C15240 Genetic Counseling).
• Secondary prevention: Early recognition of the clinical triad (microcephaly + short stature + hypoglycemia/diabetes) enables earlier initiation of metabolic management, potentially preventing acute hypoglycemic neurological injury in infancy.
• Screening: No population-level newborn or carrier screening program exists for this ultra-rare gene; targeted familial cascade testing is the only applicable "screening" approach once a proband is identified.
• Behavioral/public health interventions: Not applicable — no modifiable environmental risk factor has been identified.

14. Other Species / Natural Disease

No naturally occurring veterinary/companion-animal disease caused by TRMT10A mutation was identified in the sources searched (no OMIA entry surfaced). This appears to be a disease characterized essentially exclusively through human clinical genetics to date; a systematic OMIA search was not exhaustively completed in this pass and should be verified independently before asserting a negative finding in the knowledge base.

15. Model Organisms

Cellular/in vitro models: - siRNA knockdown of TRMT10A in rat and human β-cell lines — directly demonstrated increased β-cell apoptosis upon TRMT10A silencing, providing the primary functional/mechanistic evidence for the β-cell-loss arm of pathophysiology (Igoillo-Esteve et al. 2013). Evidence source classification: IN_VITRO. - Recombinant enzyme assays quantifying loss of m¹G9 methylation activity for the G206R mutant (>10⁴-fold reduction vs. wild type) (Gillis et al. 2014). Evidence source: IN_VITRO (biochemical/COMPUTATIONAL-adjacent enzymatic assay).

Animal models: - IMPC (International Mouse Phenotyping Consortium) Trmt10a knockout mouse (MGI:1920421) — systematic phenotyping identified significant abnormalities across multiple physiological systems, specifically including homeostasis/metabolism, growth/size/body region, skeleton, behavior/neurological, and vision/eye systems, with 11 significant phenotypes reported and 2 associated diseases linked to the gene in the IMPC database. This provides model-organism-level support (fidelity: likely MODERATE, given it is a systematic phenotyping-pipeline knockout rather than a disease-mechanism-focused study) for the growth, metabolic, and neurological dimensions of the human syndrome. Evidence source: MODEL_ORGANISM. - No detailed IMPC phenotype table (specific glucose-tolerance-test results, body-weight curves, etc.) was retrievable in this pass due to dynamically loaded content; a curator populating a knowledge-base animal_models block should fetch the full IMPC data table directly (https://www.mousephenotype.org/data/genes/MGI:1920421) before finalizing specific readout values, rather than relying on this summary alone.

Notable limitation: No zebrafish, Drosophila, or C. elegans model specific to TRMT10A/MSSGM1 was identified in the sources reviewed (contrast with NSMCE2, where a zebrafish knockdown model exists — but that is a different, non-orthologous disease gene, and should not be conflated with TRMT10A model-organism evidence in the knowledge base).

Applications: The β-cell siRNA-knockdown model directly supports research into the apoptotic mechanism underlying the hypoglycemia-to-diabetes transition; the IMPC mouse knockout supports broader phenotype-recapitulation (growth, metabolism, neurological) but has not yet been used, per the sources found here, for a dedicated mechanistic dissection of the neurodevelopmental (microcephaly) arm of the human disease.

Summary of Key Ontology Term Suggestions for Knowledge-Base Curation

Important curation note: Before final entry, all PMIDs above should be re-verified against just fetch-reference and cached abstracts per the dismech evidence SOP — in particular, this research pass was unable to independently confirm the exact PMID for Gillis et al. 2014 (J Med Genet 51:581–586; DOI: 10.1136/jmedgenet-2014-102282) through the tools available and it is cited here by DOI/journal citation rather than a verified PMID; a curator should resolve this PMID via PubMed/just fetch-reference before use, and must independently verify NEC risk against the two similarly-named but distinct entities (MSSGM2/IGF2BP1 and NSMCE2-related primordial dwarfism) given their overlapping phenotype and eponym-adjacent naming pattern.

Sources (consolidated): - OMIM #616033 — MSSGM1 - OMIM *616013 — TRMT10A - MedGen C4014997 - Orphanet — TRMT10A - Igoillo-Esteve et al. 2013, PLOS Genetics, PMID 24204302 (PMC3814312) - Gillis et al. 2014, J Med Genet 51:581–586 (DOI 10.1136/jmedgenet-2014-102282) - Yew et al. 2016, Diabetic Medicine, PMID 26526202 (PMC4995728) - Lin et al. 2020, BMJ Open Diabetes Res Care (PMC7569974) - Zung et al. 2015, Am J Med Genet A - TRMT10A Mutation... Hypoplastic Kidneys, PMID 33448213 - A rare syndrome: Microcephaly, diabetes mellitus, and epilepsy, PMID 38302348 - TRMT10A-Related Neurodevelopmental Disorder Without Metabolic Findings, Human Mutation 2026 - IMPC Trmt10a knockout mouse, MGI:1920421 - GenCC TRMT10A - GeneCards TRMT10A

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.